Imeik Technology Development Co Ltd is engaged in Research and development, production and sales of biomedical materials and biopharmaceuticals.
2004
1.2K+
LTM Revenue $406M
LTM EBITDA $288M
$7.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Imeik Technology Development has a last 12-month revenue (LTM) of $406M and a last 12-month EBITDA of $288M.
In the most recent fiscal year, Imeik Technology Development achieved revenue of $421M and an EBITDA of $324M.
Imeik Technology Development expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Imeik Technology Development valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $406M | XXX | $421M | XXX | XXX | XXX |
Gross Profit | $382M | XXX | $399M | XXX | XXX | XXX |
Gross Margin | 94% | XXX | 95% | XXX | XXX | XXX |
EBITDA | $288M | XXX | $324M | XXX | XXX | XXX |
EBITDA Margin | 71% | XXX | 77% | XXX | XXX | XXX |
EBIT | $294M | XXX | $301M | XXX | XXX | XXX |
EBIT Margin | 72% | XXX | 71% | XXX | XXX | XXX |
Net Profit | $256M | XXX | $273M | XXX | XXX | XXX |
Net Margin | 63% | XXX | 65% | XXX | XXX | XXX |
Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Imeik Technology Development's stock price is CNY 194 (or $27).
Imeik Technology Development has current market cap of CNY 58.7B (or $8.2B), and EV of CNY 55.7B (or $7.8B).
See Imeik Technology Development trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$7.8B | $8.2B | XXX | XXX | XXX | XXX | $0.85 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Imeik Technology Development has market cap of $8.2B and EV of $7.8B.
Imeik Technology Development's trades at 18.4x EV/Revenue multiple, and 23.9x EV/EBITDA.
Equity research analysts estimate Imeik Technology Development's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Imeik Technology Development has a P/E ratio of 32.0x.
See valuation multiples for Imeik Technology Development and 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $8.2B | XXX | $8.2B | XXX | XXX | XXX |
EV (current) | $7.8B | XXX | $7.8B | XXX | XXX | XXX |
EV/Revenue | 19.1x | XXX | 18.4x | XXX | XXX | XXX |
EV/EBITDA | 26.9x | XXX | 23.9x | XXX | XXX | XXX |
EV/EBIT | 26.4x | XXX | 25.8x | XXX | XXX | XXX |
EV/Gross Profit | 20.3x | XXX | n/a | XXX | XXX | XXX |
P/E | 32.0x | XXX | 30.0x | XXX | XXX | XXX |
EV/FCF | 35.1x | XXX | 33.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImeik Technology Development's last 12 month revenue growth is 7%
Imeik Technology Development's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Imeik Technology Development's rule of 40 is 84% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Imeik Technology Development's rule of X is 89% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Imeik Technology Development and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 7% | XXX | 4% | XXX | XXX | XXX |
EBITDA Margin | 71% | XXX | 77% | XXX | XXX | XXX |
EBITDA Growth | 5% | XXX | -5% | XXX | XXX | XXX |
Rule of 40 | 84% | XXX | 84% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 89% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Imeik Technology Development acquired XXX companies to date.
Last acquisition by Imeik Technology Development was XXXXXXXX, XXXXX XXXXX XXXXXX . Imeik Technology Development acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was Imeik Technology Development founded? | Imeik Technology Development was founded in 2004. |
Where is Imeik Technology Development headquartered? | Imeik Technology Development is headquartered in China. |
How many employees does Imeik Technology Development have? | As of today, Imeik Technology Development has 1.2K+ employees. |
Is Imeik Technology Development publicy listed? | Yes, Imeik Technology Development is a public company listed on SHE. |
What is the stock symbol of Imeik Technology Development? | Imeik Technology Development trades under 300896 ticker. |
When did Imeik Technology Development go public? | Imeik Technology Development went public in 2020. |
Who are competitors of Imeik Technology Development? | Similar companies to Imeik Technology Development include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
What is the current market cap of Imeik Technology Development? | Imeik Technology Development's current market cap is $8.2B |
What is the current revenue of Imeik Technology Development? | Imeik Technology Development's last 12 months revenue is $406M. |
What is the current revenue growth of Imeik Technology Development? | Imeik Technology Development revenue growth (NTM/LTM) is 7%. |
What is the current EV/Revenue multiple of Imeik Technology Development? | Current revenue multiple of Imeik Technology Development is 19.1x. |
Is Imeik Technology Development profitable? | Yes, Imeik Technology Development is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of Imeik Technology Development? | Imeik Technology Development's last 12 months EBITDA is $288M. |
What is Imeik Technology Development's EBITDA margin? | Imeik Technology Development's last 12 months EBITDA margin is 71%. |
What is the current EV/EBITDA multiple of Imeik Technology Development? | Current EBITDA multiple of Imeik Technology Development is 26.9x. |
What is the current FCF of Imeik Technology Development? | Imeik Technology Development's last 12 months FCF is $221M. |
What is Imeik Technology Development's FCF margin? | Imeik Technology Development's last 12 months FCF margin is 55%. |
What is the current EV/FCF multiple of Imeik Technology Development? | Current FCF multiple of Imeik Technology Development is 35.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.